

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
6 April 2016 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 8:30 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drugs/drug classes during the February 2016 meeting:

- ***Designated Newly-Approved Drugs***
 - ***Non-basal Insulins: Inhaled human insulin (Afrezza)***
 - ***Non-steroidal Anti-inflammatory Drugs (NSAIDs): Indomethacin low dose 20 mg and 40 mg capsules (Tivorbex)***
 - ***Long-Acting Beta Agonists (LABAs): Olodaterol oral inhaler (Striverdi Respimat)***
 - ***Ophthalmic-1 Agents: Olopatadine 0.7% ophthalmic solution (Pazeo)***
- ***Drug Class Reviews***
 - ***Contraceptive Agents: Oral Contraceptive Products (OCPs) and Miscellaneous Contraceptives***
 - ***Antifungals: Topical Lacquers***
 - ***Ophthalmic Anti-inflammatory/Immunomodulatory Agents—Ophthalmic Immunomodulatory Agents: Cyclosporine 0.05% ophthalmic emulsion (Restasis)***
- ***Innovator Drugs***
 - ***Oral Oncology Agents—Lung Cancer: Alectinib (Alecensa)***
 - ***Attention Deficit Hyperactivity Disorder (ADHD)—Stimulants: Amphetamine ER oral suspension (Dyanavel XR)***

- **Antihemophilic Agents: Antihemophilic factor, recombinant (rFVIII) injection (Adynovate)**
- **Metabolic Replacement Agents: Asfotase alfa injection (Strensiq)**
- **Anti-platelet Agents: Aspirin ER 162.5 mg (Durlaza)**
- **Antihemophilic Agents: Coagulation Factor X injection (Coagadex)**
- **Oral Oncology Agents—Metastatic Melanoma: Cobimetinib (Cotellic)**
- **Anti-Retrovirals: Elvitegravir/cobicistat/emtricitabine/tenofovir/ alafenamide (Genvoya)**
- **Pulmonary II—LABAs: Glycopyrrolate oral inhaler (Seebri Neohaler)**
- **Pulmonary II—LABAs/Long-Acting Muscarinic Agents (LAMAs): Indacaterol/glycopyrrolate oral inhaler (Utibron Neohaler)**
- **Basal Insulins: Insulin degludec (Tresiba)**
- **Oral Oncology Agents—Multiple Myeloma: Ixazomib (Ninlaro)**
- **NSAIDs: Meloxicam low dose 5 mg and 10 mg (Vivlodex)**
- **Alcohol Deterrents/Narcotic Antagonists: Naloxone nasal spray (Narcan Nasal)**
- **Oral Oncology Agents—Non-Small Cell Lung Cancer (NSCLC): Osimertinib (Tagrisso)**
- **Binders/Chelators/Antidotes/Overdose Agents: Patiromer (Veltassa)**
- **Anti-emetics: Rolapitant (Varubi)**
- **Pulmonary Arterial Hypertension Agents: Selexipag (Uptravi)**
- **Utilization Management Issues**
 - **Prior Authorization Criteria**
 - **Gastrointestinal-2 (GI-2) Miscellaneous Drugs: Eluxadoline (Viberzi)**
 - **Atypical Antipsychotics (AAPs): Brexpiprazole (Rexulti)**
 - **Anticonvulsants: Lacosamide (Vimpat)**
 - **Renin-Angiotensin Antihypertensive Agents (RAAs): Sacubitril/valsartan (Entresto)**
 - **Targeted Immunomodulatory Biologics (TIBs): Secukinumab injection (Cosentyx)**
- **Over-the-Counter Drugs**
 - **Doxylamine**
- **NDAA 2007 Section 703 Actions**

➤ **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.